Cogent Biosciences (COGT) Total Current Liabilities (2017 - 2026)
Cogent Biosciences (COGT) posted quarterly Total Current Liabilities of $58.0 million for Q1 2026, up 17.57% year-over-year from $49.3 million in Q1 2025, and down 9.34% quarter-over-quarter from $64.0 million in Q4 2025.
Cogent Biosciences (COGT) Total Current Liabilities (2017 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Total Current Liabilities for 10 consecutive years, with $58.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 17.57% year-over-year to $58.0 million; the TTM figure through Mar 2026 stood at $58.0 million (up 17.57% YoY), while the FY2025 annual figure was $64.0 million, up 14.8% from the prior year.
- Total Current Liabilities fell to $58.0 million in Q1 2026 per COGT's latest filing, from $64.0 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $64.0 million in Q4 2025 and bottomed at $17.9 million in Q1 2022.
- Historically, Total Current Liabilities has averaged $40.8 million across 5 years, with a median of $38.2 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities surged 116.93% — and 2023, when it declined 6.87%.
- Cogent Biosciences' Total Current Liabilities stood at $26.8 million in 2022, then surged by 42.16% to $38.2 million in 2023, then jumped by 45.96% to $55.7 million in 2024, then climbed by 14.8% to $64.0 million in 2025, then slipped by 9.34% to $58.0 million in 2026.
- Business Quant data shows COGT's Total Current Liabilities at $58.0 million in Q1 2026, $64.0 million in Q4 2025, and $62.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 59.30 Mn |
| Mar 31, 2026 | 57.98 Mn |
| Dec 31, 2025 | 63.95 Mn |
| Sep 30, 2025 | 62.25 Mn |
| Jun 30, 2025 | 58.42 Mn |
| Mar 31, 2025 | 49.32 Mn |
| Dec 31, 2024 | 55.71 Mn |
| Sep 30, 2024 | 53.05 Mn |
| Jun 30, 2024 | 40.00 Mn |
| Mar 31, 2024 | 36.69 Mn |
| Dec 31, 2023 | 38.17 Mn |
| Sep 30, 2023 | 34.72 Mn |
| Jun 30, 2023 | 25.76 Mn |
| Mar 31, 2023 | 21.12 Mn |
| Dec 31, 2022 | 26.85 Mn |
| Sep 30, 2022 | 23.55 Mn |
| Jun 30, 2022 | 27.66 Mn |
| Mar 31, 2022 | 17.88 Mn |
| Dec 31, 2021 | 17.08 Mn |
| Sep 30, 2021 | 16.71 Mn |